June 18 (Bloomberg) -- The following is a list of companies whose shares are having unusual price changes on U.S. exchanges. Stock symbols are in parentheses after company names. Share prices are as of 1:15 p.m. New York time.
Alcoa Inc. (AA US) rose $1.19, or 2.9 percent, to $42.79. The London-based Times said BHP Billiton Ltd. may consider a $40 billion takeover of the U.S. aluminum maker. BHP is in the early stages of considering an offer and hasn't made an approach to Alcoa, the newspaper reported without saying where it got the information.
Alleghany Corp. (Y US) rose $16.62, or 4.5 percent, to $387.60. Shares of the U.S. insurance and investment company that's similar to Warren Buffett's Berkshire Hathaway Inc. may surge 50 percent in the next three years, Barron's reported, without citing anyone.
American Technical Ceramics Corp. (AMK US) rose $7.09, or 42 percent, to $23.90. AVX Corp. (AVX US), a maker of electronic components controlled by Kyocera Corp., agreed to buy American Technical for $231 million, or $24.75 a share.
Apple Inc. (AAPL US) climbed $3.74, or 3.1 percent, to $124.24. The maker of Macintosh computers and iPod music players said the battery on its new iPhone will last longer than the company expected when Chief Executive Officer Steve Jobs unveiled the handset in January.
Authorize.Net Holdings Inc. (ANET US) gained 90 cents, or 5.4 percent, to $17.63. CyberSource Corp., a processor of online transactions, said it agreed to buy the company for $565 million.
Cadence Design Systems Inc. (CDNS US) lost 98 cents, or 4.2 percent, to $22.32. Blackstone Group LP and Kohlberg Kravis Roberts & Co.'s bid to buy the maker of computer-chip design software has stalled because of disagreements on a purchase price, the New York Times reported, citing people close to the matter. The talks for Cadence appear to be suspended, though they could resume in the future, according to the Times, citing the unidentified people.
China Medical Technologies Inc. American depositary receipts (CMED US), each representing 10 shares, climbed $3.68, or 14 percent, to $30.93. The maker of devices for the treatment of tumors said it earned $37.5 million in the fiscal fourth quarter. That exceeded UBS AG analyst Vicky Yun Chen's $35.9 million estimate.
CV Therapeutics Inc. (CVTX US) rose 79 cents, or 7 percent, to $12.16. The biotechnology company could be a takeover target, CNBC host Jim Cramer said on his ``Mad Money'' show.
Encysive Pharmaceuticals Inc. (ENCY US) fell $1.78, or 43 percent, to $2.32. The drugmaker lost a battle with Gilead over whose treatment for a fatal lung disease would be the first to win U.S. approval. Encysive may have to make ``significant reductions'' in its workforce because its drug, Thelin, failed to win market clearance, the company said in a statement on June 15.
Friendly Ice Cream Corp. (FRN US) jumped 81 cents, or 5.6 percent, to $15.14. The 72-year-old chain will be acquired for roughly $337.2 million by an affiliate of buyout firm Sun Capital Partners Inc.
Genesco Inc. (GCO US) rose $4.08, or 8.2 percent, to $53.68. Finish Line Inc. (FINL US) agreed to buy the owner of the Johnston & Murphy and Journeys shoe-store chains for $1.5 billion in cash. Finish Line, a sports-clothing and footwear retailer, will pay $54.50 for each Genesco share, 9.9 percent more than Genesco's stock price at the end of last week. The transaction will add to Finish Line's earnings, excluding some amortization costs, in the first year after the purchase is completed, Finish Line said. Finish Line shares fell 6.3 percent to $11.83.
Labopharm Inc. (DDSS US) rose 32 cents, or 11 percent, to $3.21. The Canadian drugmaker said in a statement distributed by PRNewswire that its once-daily tramadol was approved for sale in Canada.
Lee Enterprises Inc. (LEE US) dropped $2.22, or 9.3 percent, to $21.71. The owner of newspapers including the St. Louis Post- Dispatch forecast fiscal third-quarter profit that missed analysts' estimates because of continuing declines in advertising sales.
Lexicon Pharmaceuticals Inc. (LXRX US) rose 17 cents, or 5.5 percent, to $3.25. The Texas biotechnology company has reached an agreement with two private-equity firms, Invus Group LLC and Symphony Capital Partners LP, for as much as $610 million in drug-development financing.
National Instruments Corp. (NATI US) rose $2.18, or 6.9 percent, to $33.95. The maker of industrial test-and-measurement gear was raised to ``overweight'' from ``neutral'' by JPMorgan analyst Mark Moskowitz, who wrote in a note that the company may benefit from increased research and capital spending by semiconductor makers.
ScanSource Inc. (SCSC US) rose $3.89, or 14 percent, to $32.50. The distributor of bar-code scanners and magnetic-strip readers said it expects revenue of as much as $532 million in the fiscal fourth quarter. Five analysts in a Bloomberg survey had an average estimate of $524.1 million. The company also said it filed results for the previous three quarters as well as fiscal 2006 with the U.S. Securities and Exchange Commission after an internal probe of its accounting for stock options.
Symantec Corp. (SYMC US) rose 51 cents, or 2.6 percent, to $20.21. Goldman, Sachs & Co. raised its rating on the shares of the largest maker of anti-virus software to ``buy'' from ``neutral'' and increased the price it expects the shares to reach to $25 from $21. Analyst Sarah Friar cited the company's June 14 announcement that it would spend $2 billion to buy back about 11 percent of its outstanding shares and ``impressive upcoming releases of its flagship products.''
Tektronix Inc. (TEK US) rose $1.45, or 4.5 percent, to $33.50. The maker of test equipment for chip factories was boosted to ``overweight'' from ``underweight'' by analyst Mark Moskowitz at JPMorgan.
Wendy's International Inc. (WEN US) fell $1.25, or 3.2 percent, to $38.48. The third-largest U.S. hamburger chain reduced its profit forecast and said a board committee will consider a sale of the company. Earnings this year will be $1.09 to $1.23 a share, compared with a previous forecast of as much as $1.32, Wendy's said in a statement. Analysts estimate profit of $1.28, the average of 14 projections compiled by Bloomberg.
No comments:
Post a Comment